» Articles » PMID: 33839224

Cyclodextrin Dimers: A Versatile Approach to Optimizing Encapsulation and Their Application to Therapeutic Extraction of Toxic Oxysterols

Overview
Journal Int J Pharm
Specialties Chemistry
Pharmacology
Date 2021 Apr 11
PMID 33839224
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

We have developed a novel class of specifically engineered, dimerized cyclodextrin (CD) nanostructures for the encapsulation of toxic biomolecules such as 7-ketocholesterol (7KC). 7KC accumulates over time and causes dysfunction in many cell types, linking it to several age-related diseases including atherosclerosis and age-related macular degeneration (AMD). Presently, treatments for these diseases are invasive, expensive, and show limited benefits. CDs are cyclic glucose oligomers utilized to capture small, hydrophobic molecules. Here, a combination of in silico, in vitro, and ex vivo methods is used to implement a synergistic rational drug design strategy for developing CDs to remove atherogenic 7KC from cells and tissues. Mechanisms by which CDs encapsulate sterols are discussed, and we conclude that covalently linked head-to-head dimers of βCDs have substantially improved affinity for 7KC compared to monomers. We find that inclusion complexes can be stabilized or destabilized in ways that allow the design of CD dimers with increased 7KC selectivity while maintaining an excellent safety profile. These CD dimers are being developed as therapeutics to treat atherosclerosis and other debilitating diseases of aging.

Citing Articles

Anti-inflammatory effects of cyclodextrin nanoparticles enable macrophage repolarization and reduce inflammation.

Brettner F, Gier S, Haessler A, Schreiner J, Vogel-Kindgen S, Windbergs M Discov Nano. 2024; 19(1):211.

PMID: 39707045 PMC: 11662127. DOI: 10.1186/s11671-024-04175-6.


Cyclodextrin Dimers Functionalized with Biotin as Nanocapsules for Active Doxorubicin Delivery Against MCF-7 Breast Cell Line.

Bognanni N, Scuderi C, Giglio V, Spiteri F, La Piana L, Condorelli D ChemMedChem. 2024; 19(24):e202400368.

PMID: 39246269 PMC: 11648824. DOI: 10.1002/cmdc.202400368.


Cyclodextrins: Establishing building blocks for AI-driven drug design by determining affinity constants .

Anderson A, Pineiro A, Garcia-Fandino R, OConnor M Comput Struct Biotechnol J. 2024; 23:1117-1128.

PMID: 38510974 PMC: 10950811. DOI: 10.1016/j.csbj.2024.02.011.


Unraveling lipid and inflammation interplay in cancer, aging and infection for novel theranostic approaches.

Conde-Torres D, Blanco-Gonzalez A, Seco-Gonzalez A, Suarez-Leston F, Cabezon A, Antelo-Riveiro P Front Immunol. 2024; 15:1320779.

PMID: 38361953 PMC: 10867256. DOI: 10.3389/fimmu.2024.1320779.


Selective Removal of 7KC by a Novel Atherosclerosis Therapeutic Candidate Reverts Foam Cells to a Macrophage-like Phenotype.

Bhargava P, Dinh D, Teramayi F, Silberg A, Petler N, Anderson A bioRxiv. 2023; .

PMID: 37961383 PMC: 10634755. DOI: 10.1101/2023.10.23.563623.